Beijing Beilu Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. It provides contrast agents, such as Iohexol injection, Gadolinol injection, Gadopentetate Dimeglumine injection, Iodixanol injection, and Iopamidol injection; Jiuweizhenxin granule, a central nervous system product; and oral anti-diabetic drugs, including Glimepiride tablets and Repaglinide tablets. The company was founded in 1992 and is based in Beijing, China.
Research context
Beijing Beilu Pharmaceutical Co., Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Beijing Beilu Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 11.0% below its 200 day moving average.
From a valuation standpoint, the stock is 43.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.4.
Beijing Beilu Pharmaceutical Co., Ltd's total revenue sank by 3.6% to $204M since the same quarter in the previous year.
Its net income has dropped by 91.9% to $14M since the same quarter in the previous year.
Finally, its free cash flow fell by 96.0% to $1M since the same quarter in the previous year.
Based on the above factors, Beijing Beilu Pharmaceutical Co., Ltd gets an overall score of 1/5.